Key Takeaways
- • Ken Griffin's Citadel increased its AbbVie (NYSE: ABBV) position by 547% through the purchase of 2.68 million additional shares, demonstrating continued conviction in the healthcare dividend stock at a lower valuation than current levels.
- • Citadel acquired the AbbVie shares at an average price of $214.90 per share, while the stock currently trades at approximately $260 per share, reflecting a 21% unrealized gain on the recent position increase.
- • AbbVie qualifies as a Dividend King with 53 consecutive years of dividend increases (including its tenure as an Abbott Labs subsidiary), and raised its quarterly dividend by 5.5% to $1.73 in 2026, offering a current yield of approximately 2.8%.
- • Griffin's Citadel fund generated 14% returns in July 2026, a strong performance period during which the fund also acquired most of Situational Awareness' public stock portfolio, underscoring the fund's active rebalancing strategy.
- • AbbVie management maintains a commitment to its A2/A- credit rating and plans to achieve approximately two times net leverage within two to three years following debt paydown, signaling financial discipline and dividend sustainability.
Summary
Billionaire hedge fund manager Ken Griffin made a significant move in the healthcare sector in late July 2026, substantially increasing Citadel's exposure to AbbVie, a diversified biopharmaceutical company. The position increase, achieved through the purchase of 2.68 million shares, represents a 547% expansion of Citadel's existing stake. This acquisition reflects Griffin's established investment philosophy of identifying undervalued equities with strong fundamentals and long-term return potential.
The timing and valuation of this transaction demonstrate disciplined capital deployment. Citadel executed the share purchases at an average cost of $214.90 per share, while AbbVie currently trades near $260, generating immediate unrealized gains of approximately 21% on this specific tranche. This spread reflects the price appreciation since the acquisition and reinforces Griffin's historical track record of buying at discounted valuations. The move is particularly noteworthy given that Citadel has maintained an ownership stake in AbbVie since the company's 2013 spinoff from Abbott Labs, indicating sustained confidence in management execution and business fundamentals.
AbbVie's credentials as a dividend aristocrat add strategic weight to this position increase. The company holds Dividend King status—a designation reserved for firms that have increased dividends for 50 or more consecutive years—with 53 consecutive years of increases when accounting for its history as an Abbott subsidiary. In 2026, AbbVie raised its quarterly dividend by 5.5% to $1.73 per share, translating to a current yield of approximately 2.8% at prevailing market prices. Since its 2013 spinoff, AbbVie has increased aggregate dividend payouts by more than 330%, demonstrating consistent capital returns to shareholders and financial flexibility.
Importantly, AbbVie's management has signaled financial discipline and dividend sustainability through its stated commitment to maintain its A2/A- credit rating and achieve approximately two times net leverage within two to three years following debt reduction from the recent acquisition financing. This conservative leverage target supports the company's capacity to sustain and grow dividends through economic cycles. Citadel's July performance—which saw the fund rise 14% during a challenging month for the broader hedge fund industry—provides context for the firm's strong capital base and investment acumen during this position increase.
The timing and valuation of this transaction demonstrate disciplined capital deployment. Citadel executed the share purchases at an average cost of $214.90 per share, while AbbVie currently trades near $260, generating immediate unrealized gains of approximately 21% on this specific tranche. This spread reflects the price appreciation since the acquisition and reinforces Griffin's historical track record of buying at discounted valuations. The move is particularly noteworthy given that Citadel has maintained an ownership stake in AbbVie since the company's 2013 spinoff from Abbott Labs, indicating sustained confidence in management execution and business fundamentals.
AbbVie's credentials as a dividend aristocrat add strategic weight to this position increase. The company holds Dividend King status—a designation reserved for firms that have increased dividends for 50 or more consecutive years—with 53 consecutive years of increases when accounting for its history as an Abbott subsidiary. In 2026, AbbVie raised its quarterly dividend by 5.5% to $1.73 per share, translating to a current yield of approximately 2.8% at prevailing market prices. Since its 2013 spinoff, AbbVie has increased aggregate dividend payouts by more than 330%, demonstrating consistent capital returns to shareholders and financial flexibility.
Importantly, AbbVie's management has signaled financial discipline and dividend sustainability through its stated commitment to maintain its A2/A- credit rating and achieve approximately two times net leverage within two to three years following debt reduction from the recent acquisition financing. This conservative leverage target supports the company's capacity to sustain and grow dividends through economic cycles. Citadel's July performance—which saw the fund rise 14% during a challenging month for the broader hedge fund industry—provides context for the firm's strong capital base and investment acumen during this position increase.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.